IGC Pharma (IGC) Assets Average (2011 - 2026)

IGC Pharma (IGC) has 16 years of Assets Average data on file, last reported at $9.4 million in Q1 2026.

• Assets Average for Q1 2026 came in at $9.4 million, up 6.01% year-over-year; the trailing twelve-month figure through Mar 2026 was $9.4 million (up 6.01% YoY), and the FY2026 annual result was $9.0 million, down 3.84% from the prior year.
• Assets Average eased to $9.4 million in Q1 2026 per IGC's latest filing, from $9.7 million in the prior quarter.
• Over five years, Assets Average peaked at $29.1 million in Q1 2022 and troughed at $8.3 million in Q2 2025.
• A 5-year average of $14.7 million and a median of $10.6 million in 2024 frame the typical range for Assets Average.
• The sharpest annual moves came in 2024 and 2026: Assets Average slumped 43.19% in 2024, then gained 6.01% in 2026.
• A 5-year view of Assets Average shows it stood at $21.0 million in 2022, then slumped by 33.94% to $13.9 million in 2023, then declined by 29.96% to $9.7 million in 2024, then gained by 0.04% to $9.7 million in 2025, then dropped by 2.87% to $9.4 million in 2026.
• Business Quant data shows IGC's Assets Average at $9.4 million in Q1 2026, $9.7 million in Q4 2025, and $8.8 million in Q3 2025.